IV Secukinumab Trials Hit Primary Endpoints in PsA, AxSpA
Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy vs placebo in treating psoriatic arthritis and axial spondyloarthritis.
New York United States Alanj Kivitz Assessment Of The Spondyloarthritis International Society American College Of Rheumatology Clinical Research
Source: medscape.com